

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time	Wednesday 20th May 2020, 1pm
Venue	Conference Call
Chair	Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No (Approval to be sought from secondary care clinician post meeting)

Miss J Morgan, Senior Principal Pharmacist, HUTH
Dr R Schreiber, Medical Secretary, LMC
Ms M Opoku-Fofie, Pharmacist, HFTH
Mr K McCorry, Senior Pharmacist, NECS
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HUTH
Dr B Ali, GP Prescribing Lead, Hull
Mrs J Stark, Senior Pharmacist, HFTH
Ms Sumayya Kasuji, Senior Pharmacist, HUTH

Guest

Apologies	Prof A Morice, Professor of Respiratory Medicine, HUTH Mrs E Baggely, Head of Medicines Service, CHCP Mr P Davis, Strategic Lead Primary Care, Hull, CCG
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2020.05.01	Apologies	As above				
2020.05.02	Declarations of Interest	None				
2020.05.05	Minutes of the Previous Meeting	<p>Page 2 to be amended to say "Sativex not routinely commissioned available via IFR only"</p> <p>Group discussed the use of a different forum such as Microsoft Teams or Cisco Webex for future meetings</p>	<p>WH to amend minutes</p> <p>WH to explore the use of Microsoft teams/Cisco Webex</p>		<p>WH</p> <p>WH</p>	<p>7/2020</p> <p>7/2020</p>
2020.05.04	Matters Arising & Action Tracker	<p>RMOC JM has chased relevant HUTH departments again regarding use of heparinised saline and is awaiting a response</p> <p>Correspondence Received Rheumatology to prepare pathway for rituximab without MTX – parked until Covid crisis over</p> <p>Humber CCG Evidence Based Interventions KMc has discussed wording of documents with commissioners as it was confusing, no final document produced as yet.</p> <p>Correspondence Received RS unable to discuss use of methylphenidate SCF by private prescriber with LMC as previous two LMC meetings were taken over by COVID next meeting is in June and RS will raise this Discussion earlier this year regarding sending full SCF document to GPs, however with COVID Lorenzo system will only allow front page to be downloaded LMC have agreed with HFTH to accept this for now providing the front page states which version of the document it relates to and a link to the HERPC web page However once document has been updated on website the link would not take you to the correct version of the document.</p> <p>Tracker</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>		<p>JM</p> <p>JM</p> <p>KMc</p> <p>RS</p>	<p>1/20</p> <p>1/20</p> <p>3/20</p> <p>3/20</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>WH has circulated SCF feedback to committee</p> <p>Traffic Light Status Lurasidone was discussed by D&T. JS said originally Lurasidone was declined by HFTH DTCs for general use but approved on a named patient basis. Patient presented at HUTH and HUTH had to procure Lurasidone to treat patient even though it is not on formulary. JS/DC to agree wording to be added to formulary along lines of “Humber Consultant Initiation only”</p> <p>Traffic Light Status WH has added Tildrakizumab, Certolizumab Pegol and Ibandronic Acid to red list</p> <p>Traffic Light Status WH has changed Relvar to blue on joint formulary</p> <p>PG/SCF KMc has taken Liothyronine SCF to both CCG and it has been approved</p> <p>PG/SCF Primary Care Vitamin Supplementation in Liver Disease KMc has taken to both CCG and it has been approved</p> <p>PG/SCF Primary Care Vitamin Supplementation in Liver Disease JM has discussed with RENEW to ensure compliance</p> <p>PG/SCF Guidelines of Prophylaxis of Venous Thromboembolism on Transfer to Secondary Care WH has added this to website</p> <p>PG/SCF Treatment of Adult Asthma Guideline has been added to website</p>	<p>Action complete</p> <p>WH to add to red list KMc will add to Optimise</p> <p>JS/DC to agree wording for red list and inform WH</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>WH</p> <p>WH</p> <p>KMc</p> <p>JS/DC</p> <p>WH</p> <p>WH</p> <p>KMc</p> <p>KMc</p> <p>JM</p> <p>WH</p> <p>WH</p>	<p>5/20</p> <p>7/20</p> <p>7/20</p> <p>7/20</p> <p>5/20</p> <p>5/20</p> <p>5/20</p> <p>5/20</p> <p>5/20</p> <p>5/20</p>
2020.05.05	Traffic Light Status	<p>Selexipag to treat PAH in line with NHSE</p> <p>Brolucizumab to treat nAMD can be used instead of Eyelea and Lucentis and has the advantage of longer dosing schedule reducing the number</p>	<p>Approved as RED</p> <p>Approved as RED</p>	<p>WH to update formulary and red list</p>	<p>WH</p>	<p>7/20</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>of patient appointments</p> <p>Liposomal Cytarabine- Daunorubicin to treat untreated acute myeloid leukaemia in line with TA 552</p> <p>Dinoprostone Extension of use to include off license use in children with ductus arteriosus in line with BNFC</p> <p>MHRA DSU –Esmya – licensed suspended Remove from formulary</p>	<p>Approved as RED</p> <p>Approved as RED</p> <p>Remove from formulary Remove SCF Already done</p>			
2020.05.06	Feedback From Commissioning Groups	<p>Liothyronine SCF approved</p> <p>Primary Care Vitamin Supplementation in Liver approved</p> <p>Brolucizumab approved if follow same criteria for Eyelea and Lucentis until NICE approved, IFR required for other indications</p>	Noted	No further action		5/20
2020.05.07	Prescribing guidelines, shared care frameworks for approval	<p>NEW</p> <p>SCF Sandostatin analogues for high output stoma Agreed to discuss next time when prescribing guideline for HOS will also be discussed</p> <p>UPDATES</p> <p>Loading Dose Guideline UPDATE No alterations just due for review</p> <p>SCF Riluzole ALS Update Updated to improve clarity of document, including crushing tablets and different formulations and what to do in case of neutropenia.</p> <p>SCF Grazax sublingual immunotherapy Only updated to change consultant name</p> <p>Guideline Ranolazine Only change no longer regulatory requirement to carry warning card</p> <p>Guideline Prasugrel Updated to include interactions</p> <p>Non dietary Vit B 12 Deficiency Replacement Therapy Not to be added to website as HERPC cannot endorse</p>	<p>WH to add to agenda for July</p> <p>WH to add to website once approval from secondary care consultant received</p>		<p>WH</p> <p>WH</p>	<p>7/20</p> <p>7/20</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		Vitamin B12 & Bariatric Surgery During Covid 19 Outbreak Has come through due to pathway change at HUTH agreed to add to website for 6 month period to cover duration of Covid outbreak				
2020.05.08	MHRA DSU	<p>March 2020 Esmya suspension of licence due to risk of serious liver injury. Search run at practices and no stock for patients to receive. Tofacitinib new measures to reduce risk of VTE and of serious fatal infections SGLT2 inhibitors monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness Benzodiazepines and opioids reminder of risk of potentially fatal respiratory depression</p> <p>April 2020 Emphasis on use of yellow card reporting system for any ADR during the treatment of COVID patients also references no evidence linking Ibuprofen or ACE inhibitors worsening of symptoms.</p>	Noted	No further action		5/20
2020.05.10	Regional Medicines Optimisation Committee	None this month				5/20
2020.05.11	Correspondence Received	Valproate Pandemic Guidance summary of how secondary care should carry out patient reviews during pandemic.	Noted	No further action		5/20
2020.05.12	Primary Care Rebate Scheme	None to report				5/20
2020.05.13	Additional Minutes for Information	<ul style="list-style-type: none"> a)MMIG (March) b) HEY D&T (March) c) HTFT DTC d) CHCP e) Formulary Sub Group f) Hull CC Planning & Commissioning 				
2020.05.14	A.O.B	A GP had been asked to prescribe Agomelatine but it is not on formulary and went to HFTH but was not approved.				
	Date and Time of Next Meeting	Wednesday 15 th July 2020, 1pm, Room 1 QCOH				

